Drug Description in Trials / DrugBank / KEGG DRUG

  

Search results

No. 薬物名（臨床試験情報から抽出） DrugBank KEGG DRUG KEGG GENES KEGG PATHWAY 指定難病告示番号
1EU-approved roactemra----1件: 46 💬
2Roactemra1件: Tocilizumab1件: Tocilizumab 💬 1件: IL6R 💬 11件: Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬7件: 41, 44, 46, 51, 86, 107, 271 💬
3Roactemra - 162 MG - soluzione iniettabile - USO sottocutaneo - siringa preriempita 0,9ML (vetro) - 4 siringhe preriempite1件: Tocilizumab1件: Tocilizumab 💬 1件: IL6R 💬 11件: Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬2件: 46, 51 💬
4Roactemra - 20 MG/ML concentrato PER soluzione PER infusione - USO endovenoso - flaconcino (vetro) 4ML 1 flaconcino1件: Tocilizumab1件: Tocilizumab 💬 1件: IL6R 💬 11件: Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬1件: 46 💬
5Roactemra 162 MG1件: Tocilizumab1件: Tocilizumab 💬 1件: IL6R 💬 11件: Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬2件: 46, 51 💬
6Roactemra 162 MG solution FOR injection IN PRE-filled syringe1件: Tocilizumab1件: Tocilizumab 💬 1件: IL6R 💬 11件: Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬1件: 41 💬
7Roactemra 162 MG solution injectable EN seringue PRéremplie1件: Tocilizumab1件: Tocilizumab 💬 1件: IL6R 💬 11件: Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬2件: 46, 56 💬
8Roactemra 162 MG soluzione iniettabile IN siringa preriempita1件: Tocilizumab1件: Tocilizumab 💬 1件: IL6R 💬 11件: Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬1件: 50 💬
9Roactemra 20 MG/ML concentrado para solucióN para perfusióN1件: Tocilizumab1件: Tocilizumab 💬 1件: IL6R 💬 11件: Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬1件: 46 💬
10Roactemra 20 MG/ML concentrate FOR solution FOR infusion1件: Tocilizumab1件: Tocilizumab 💬 1件: IL6R 💬 11件: Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬1件: 46 💬
11Roactemra 20 MG/ML, concentrado para solucióN para perfusióN1件: Tocilizumab1件: Tocilizumab 💬 1件: IL6R 💬 11件: Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬3件: 46, 107, 271 💬
12Roactemra 20MG/ML1件: Tocilizumab1件: Tocilizumab 💬 1件: IL6R 💬 11件: Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬1件: 40 💬
13Roactemra® 20MG/ML konzentrat1件: Tocilizumab1件: Tocilizumab 💬 1件: IL6R 💬 11件: Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬1件: 266 💬
14Roactemra®EV 1件: Tocilizumab1件: Tocilizumab 💬 1件: IL6R 💬 11件: Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬1件: 46 💬